content: <HTML><HEAD>
  <TITLE>Prepared by R.R. Donnelley Financial -- Form 8-K</TITLE>
  </HEAD>
    <BODY BGCOLOR="WHITE">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR SIZE="4" NOSHADE COLOR="#000000" ALIGN="left"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES
  AND EXCHANGE COMMISSION </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR NOSHADE WIDTH="21%"
  COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman"
  SIZE="3"><B>CURRENT REPORT </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT
  OF 1934 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported): April 24, 2002 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV>
  <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>CONCEPTUS, INC. </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in charter) </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">
  
  <TR>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware<BR></B>&nbsp;(State or other jurisdiction of incorporation or organization)</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-27596<BR></B>&nbsp;(Commission file number)</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="top" ALIGN="center" WIDTH="31%"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>97-3170244<BR></B>&nbsp;(I.R.S. employer identification no.)</FONT></DIV> </TD> </TR>
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>1021 Howard Avenue </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman"
  SIZE="2"><B>San Carlos, CA 94070 </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip code) </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (650) 802-7240 </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR NOSHADE WIDTH="21%" COLOR="#000000"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <HR
  SIZE="4" NOSHADE COLOR="#000000" ALIGN="left"><DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <P></P>
  
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"><B>ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp;OTHER EVENTS. </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">On April 24, 2002, Conceptus, Inc. issued a press release announcing financial results for the three months ended March 31, 2002. Text of the press release follows: </FONT></DIV>
  <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2"><B>SAN CARLOS, Calif. (April 24, 2002) &#151; Conceptus, Inc. (NASDAQ NM: CPTS), </B>developer of the non-incisional permanent birth control procedure
  <I>Essure</I><I></I></FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>&#153;</SUP></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><SUP></SUP>, today announced financial results for the three months ended March 31, 2002. Highlights of
  the 2002 first quarter and recent weeks include: </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="027"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD WIDTH="008" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></DIV></TD>
  <TD WIDTH="006" VALIGN="top"><DIV>&nbsp;</DIV></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">Early submission of the final Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for<I> Essure</I></FONT><FONT FACE="Times New Roman" SIZE="1"
  COLOR="#000000"><I><SUP>&#153;</SUP></I></FONT><FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><I><SUP></SUP></I> </FONT></DIV> </TD></TR></TABLE>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="027"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD WIDTH="008" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></DIV></TD>
  <TD WIDTH="006" VALIGN="top"><DIV>&nbsp;</DIV></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">Achievement of more than 900 woman-years of effectiveness testing in clinical trials with 0 reported pregnancies among women relying on <I>Essure</I> </FONT></DIV>
  </TD></TR></TABLE>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="027"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD WIDTH="008" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></DIV></TD>
  <TD WIDTH="006" VALIGN="top"><DIV>&nbsp;</DIV></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">Launch of <I>Essure</I> in certain European countries and in Canada by engagement of well established independent distributors with an existing franchise in gynecology
  </FONT></DIV> </TD></TR></TABLE>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="027"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD WIDTH="008" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></DIV></TD>
  <TD WIDTH="006" VALIGN="top"><DIV>&nbsp;</DIV></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">Expansion of the Company&#146;s direct-to-consumer (DTC) activities in Australia with a fully functioning consumer call center staffed by healthcare professionals </FONT></DIV>
  </TD></TR></TABLE> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">For the 2002 first quarter, the Company reported a net loss of $5.9 million, or $0.36 per share, compared with a net loss of $4.1 million, or $0.35
  per share, in the comparable period last year. Net sales for the first quarter of 2002 were $276,000, compared with no sales in the first quarter last year; on a sequential-quarter basis, sales of <I>Essure </I>more than doubled. Approximately
  $110,000 in first quarter 2002 net sales were derived from Europe, of which approximately 50 percent represented first-time orders from distributors, as the Company introduced <I>Essure </I>in several European markets. Cost of sales and start-up
  manufacturing costs were $746,000 in the 2002 first quarter, representing the cost of early stage product introductions and limited production volumes. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman"
  SIZE="2">Owing to lower pivotal trial costs, research and development expenses were $2.0 million for the 2002 first quarter, compared with $2.2 million in the prior year&#146;s first quarter. Selling, general and administrative expenses were $3.2
  million for the three months ended March 31, 2002, compared with $2.1 million last year. The increase was related to sales and marketing activities as the Company introduced <I>Essure </I>in the U.K., Northern Ireland, Spain, Portugal, Finland,
  Holland, Belgium and Canada, and continued marketing of <I>Essure </I>in Australia. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">Cash, cash equivalents, short-term investments and restricted cash
  were $26.5 million as of March 31, 2002, compared with $33.8 million as of December 31, 2001. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">&#147;The past few months have been a time of critically
  important commercial and regulatory progress at Conceptus,&#148; said Steven Bacich, chief executive officer. &#147;Much of Conceptus is tightly focused on preparing for an anticipated launch of <I>Essure </I>in the U.S., making sure manufacturing,
  sales and marketing are in place for a successful market introduction and beyond. Of particular note, last week we reached a tremendous milestone in submitting the <I>Essure </I>PMA. Clinical data included in our submission will be presented on May
  7, 2002 by Professor Rafael </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT FACE="Times New Roman" SIZE="2">Valle, M.D., Northwestern Medical School, at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, being held in Los
  Angeles.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One key data finding in our PMA submission was the verification of Conceptus&#146; commercial training program, which to date has yielded similar placement success rates
  to those reported by our Pivotal Trial clinical investigators, when compared for the first 10 cases.&#148; </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">&#147;In addition, we are very pleased with
  the initial introduction of <I>Essure </I>in Europe, and in close cooperation with our growing distribution network we are working to bring this important method of permanent birth control now to the women of Denmark, Sweden and Germany. There will
  be four clinical presentations and a separate symposium on the <I>Essure </I>system at the European Society of Gynecological Endoscopy meeting in Berlin, being held April 26-28,&#148; continued Mr. Bacich. </FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">&#147;Our McKesson telephone call center in Australia, designed to provide women with information about permanent birth control options and to answer their questions about
  <I>Essure,</I> is fully staffed by healthcare professionals and is off to a strong start. Since its opening in March, we have been able to ease the bottleneck at the General Practitioner level as women may now be initially directed to OB/GYNs
  trained in the <I>Essure </I>procedure. We plan to incorporate a similar call center format in other countries, including the United States. In addition, we have continued to market directly to the public hospitals in Australia, which represent
  about 70 percent of that nation&#146;s tubal ligation procedures, and now are active in public hospitals in every major region there,&#148; Mr. Bacich added. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman"
  SIZE="2">Separately, the Company announced that it has filed suit against Ovion, Inc. seeking a Declaratory Judgment of Patent Non-Infringement, Invalidity and Unenforceability against Ovion&#146;s Patent 6,096,052. &#147;We had already requested an
  interference in the Patent Office in this matter and we plan to vigorously protect our intellectual property rights. Our <I>Essure </I>device is our first commercial product for permanent contraception and we have no intention of allowing others to
  claim rights to our technology, which we have all worked so diligently to develop and bring to market,&#148; commented Mr. Bacich. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">Conceptus has
  scheduled an investor conference call to discuss this announcement beginning at 4:30 p.m. Eastern Time today. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company&#146;s Website,
  www.conceptus.com. A replay will be available on the Website for 30 days. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">A.&nbsp;&nbsp;&nbsp;&nbsp;PERMANENT BIRTH CONTROL
  </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">Surgical tubal ligation has become the most common form of birth control worldwide, despite the fact that it is invasive and costly. About 92 percent of
  the laparoscopic procedures in the U.S. are performed in a hospital or surgi-center under general anesthesia, requiring between three and four hours of hospital recovery time and four to six days, before returning to regular activities and an
  average of 10 days for procedures performed via laparotomy. Development of a non-incisional method of tubal ligation has been an elusive goal for researchers since the 1970&#146;s. </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">An <I>Essure </I>procedure does not require cutting or penetrating the abdomen and can be performed in a less costly
  procedure setting without general anesthesia. Accordingly, a woman is expected to average about 35 minutes pre-op to post-op for an <I>Essure</I> procedure and to return home about 45 minutes after the procedure is completed. 92 percent of
  <I>Essure</I> patients who were employed returned to work in one day or less, excluding the day of the procedure. Reliance on <I>Essure</I> does not involve taking drugs or hormones. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">B.&nbsp;&nbsp;&nbsp;&nbsp;ABOUT CONCEPTUS </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">Conceptus, Inc. is developing <I>Essure</I>, an
  investigational medical procedure, designed to provide a non-incisional alternative to tubal ligation, the leading form of birth control worldwide. <I>Essure</I> is currently an investigational device in the United States. </FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">Data from the United Nations show that worldwide, 19 percent of reproductive couples using birth control rely on surgical tubal ligation. Additionally, a survey performed by the
  United States Centers for Disease Control and Prevention indicates that surgical tubal ligation continues to be the most prevalent form of birth control in the U.S., and that 41 percent of women age 35-39 and 50 percent of women age 40-44 have had a
  surgical tubal sterilization. An estimated 700,000 surgical tubal ligations are performed each year in the United States. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman" SIZE="2">The <I>Essure </I>procedure is
  based on a unique and proprietary catheter delivery system for minimally invasive transcervical tubal access. </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2"><I>Except for the
  historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product
  development programs, and clinical efficacy of and market demand for our product, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be
  based upon factors such as strategic planning decisions by management, re-allocation of internal resources, performance of independent distributors, delays by regulatory authorities, scientific advances by third parties, introduction of competitive
  products, as well as those factors set forth in the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and Exchange Commission. </I></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Tables to Follow) </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Conceptus, Inc. </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT
  FACE="Times New Roman" SIZE="2"><B>Condensed Consolidated Statements of Operations </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(In thousands, except per share amounts) </B></FONT></DIV> <DIV><FONT
  SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
  
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months Ended March 31,</B></FONT></DIV> <HR SIZE="2" NOSHADE COLOR="#000000"></TD>
  <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2002</B></FONT></DIV> <HR SIZE="2" NOSHADE COLOR="#000000"></TD>
  <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>2001</B></FONT></DIV> <HR SIZE="2" NOSHADE COLOR="#000000"></TD>
  <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Net sales</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">276</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Operating costs and expenses:</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:40px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Cost of sales and start-up manufacturing costs</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">746</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:40px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Research and development</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,982</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,189</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:40px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Selling, general and administrative</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,214</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,054</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:40px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Total operating costs and expenses</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5,942</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,243</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Operating loss</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(5,666</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(4,243</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Other income (expense), net</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(189</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">187</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Net loss</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(5,855</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(4,056</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Basic and diluted net loss per share</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.36</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.35</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="81%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Shares used in computing basic and diluted net loss per share</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16,471</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11,723</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
   </TABLE> </DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Conceptus, Inc. </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman"
  SIZE="2"><B>Condensed Consolidated Balance Sheets </B></FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(In thousands) </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center">
  <TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
  
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>March 31, 2002</B></FONT></DIV> <HR SIZE="2" NOSHADE COLOR="#000000"></TD>
  <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>December&nbsp;31, 2001</B></FONT></DIV> <HR SIZE="2" NOSHADE COLOR="#000000"></TD>
  <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></DIV> </TD>
  <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD COLSPAN="2"> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Cash, cash equivalents, short-term investments and restricted cash</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">26,496</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33,803</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Accounts receivable, net</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">304</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">247</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Inventories, net</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,442</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,134</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Other current assets</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">801</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">556</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Total current assets</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29,043</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">35,740</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Property and equipment, net</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,748</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,658</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Other assets</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">356</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">380</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Total assets</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31,147</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">37,778</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Total liabilities</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,372</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4,603</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Common stock and additional paid-in capital</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">118,856</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">118,397</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Other comprehensive loss</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(4</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Accumulated deficit</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(91,077</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(85,222</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">)</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Total stockholders&#146; equity</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,775</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">33,175</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR NOSHADE COLOR="#000000"></TD>
  <TD> <HR NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
  <TR BGCOLOR="#cceeff">
  <TD VALIGN="top" WIDTH="76%"> <DIV STYLE="margin-left:13px; text-indent:-13px"><FONT FACE="Times New Roman" SIZE="2">Total liabilities and stockholders&#146; equity</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">31,147</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">$</FONT></DIV> </TD>
  <TD VALIGN="bottom"> <DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">37,778</FONT></DIV> </TD>
  <TD NOWRAP VALIGN="bottom"> <DIV><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></DIV> </TD> </TR>
  <TR>
  <TD> <FONT SIZE="1">&nbsp;</FONT></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD>
  <TD VALIGN="bottom" WIDTH="3%"><FONT FACE="Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
  <TD> <HR SIZE="4" NOSHADE ALIGN="right" COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE COLOR="#000000"></TD>
  <TD> <HR SIZE="4" NOSHADE WIDTH="0" ALIGN="left" COLOR="#ffffff"></TD> </TR>
   </TABLE> </DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="013" VALIGN="top" ALIGN="left"><DIV><FONT FACE="Times New Roman" SIZE="2"><I>*</I></FONT></DIV></TD>
  <TD WIDTH="006" VALIGN="top"><DIV>&nbsp;</DIV></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2"><I>Derived from audited financial statements. </I> </FONT></DIV> </TD></TR></TABLE> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman"
  SIZE="2"># # # </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></DIV>
  
  
  <p Style='page-break-before:always'>
  <HR  SIZE="3" COLOR="#CCEEFF" WIDTH="100%" ALIGN="CENTER">
   <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV
  STYLE="text-indent:27px"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  </FONT></DIV> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="326"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD WIDTH="002%" VALIGN="top"><DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">CO</FONT></DIV></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">NCEPTUS, INC. </FONT></DIV> </TD></TR></TABLE>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="326"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD WIDTH="002%" VALIGN="top"><DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(Re</FONT></DIV></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">gistrant) </FONT></DIV> </TD></TR></TABLE> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="326"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD WIDTH="002%" VALIGN="top"><DIV ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">By</FONT></DIV></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">:<U>&nbsp;&nbsp; /s/&nbsp;&nbsp;&nbsp;&nbsp;Glen K. Furuta&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></DIV>
  </TD></TR></TABLE>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="383"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">Glen K. Furuta </FONT></DIV> </TD></TR></TABLE>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="383"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">Vice President, Finance &amp; Administration </FONT></DIV> </TD></TR></TABLE>
  <TABLE CELLPADDING="0" CELLSPACING="0">
  <TR>
  <TD WIDTH="383"><FONT SIZE="1">&nbsp;</FONT></TD>
  <TD ALIGN="left" VALIGN="top"><DIV><FONT FACE="Times New Roman" SIZE="2">and Chief Financial Officer </FONT></DIV> </TD></TR></TABLE> <DIV><FONT SIZE="1">&nbsp;</FONT></DIV> <DIV><FONT FACE="Times New Roman"
  SIZE="2">Dated:&nbsp;&nbsp;&nbsp;&nbsp;April 29, 2002 </FONT></DIV> <P></P>
   <DIV ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></DIV>
  
   </BODY></HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 55046}]
metadata_filer: {"company-data": {"conformed-name": "CONCEPTUS INC", "cik": "0000896778", "assigned-sic": "3841", "irs-number": "973170244", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27596", "film-number": "02624637"}, "business-address": {"street1": "1021 HOWARD AVE", "city": "SAN CARLOS", "state": "CA", "zip": "94070", "phone": "4158027240"}, "mail-address": {"street1": "1021 HOWARD AVENUE", "city": "SAN CARLOS", "state": "CA", "zip": "94070"}}
text: Prepared by R.R. Donnelley Financial -- Form 8-K
  SECURITIES
  AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  PURSUANT TO SECTION 13 OR 15(D) OF THE
  SECURITIES EXCHANGE ACT
  OF 1934
  Date of Report (Date of earliest event reported): April 24, 2002
  CONCEPTUS, INC.
  (Exact name of registrant as specified in charter)
  Delaware
  (State or other jurisdiction of incorporation or organization)
  000-27596
  (Commission file number)
  97-3170244
  (I.R.S. employer identification no.)
  1021 Howard Avenue
  San Carlos, CA 94070
  (Address of principal executive offices) (Zip code)
  Registrant's telephone number, including area code: (650) 802-7240
  ITEM 5.    OTHER EVENTS.
  On April 24, 2002, Conceptus, Inc. issued a press release announcing financial results for the three months ended March 31, 2002. Text of the press release follows:
  SAN CARLOS, Calif. (April 24, 2002) — Conceptus, Inc. (NASDAQ NM: CPTS),
  developer of the non-incisional permanent birth control procedure
  Essure
  ™
  , today announced financial results for the three months ended March 31, 2002. Highlights of
  the 2002 first quarter and recent weeks include:
  •
  Early submission of the final Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for
  Essure
  ™
  •
  Achievement of more than 900 woman-years of effectiveness testing in clinical trials with 0 reported pregnancies among women relying on
  Essure
  •
  Launch of
  Essure
  in certain European countries and in Canada by engagement of well established independent distributors with an existing franchise in gynecology
  •
  Expansion of the Company's direct-to-consumer (DTC) activities in Australia with a fully functioning consumer call center staffed by healthcare professionals
  For the 2002 first quarter, the Company reported a net loss of $5.9 million, or $0.36 per share, compared with a net loss of $4.1 million, or $0.35
  per share, in the comparable period last year. Net sales for the first quarter of 2002 were $276,000, compared with no sales in the first quarter last year; on a sequential-quarter basis, sales of
  Essure
  more than doubled. Approximately
  $110,000 in first quarter 2002 net sales were derived from Europe, of which approximately 50 percent represented first-time orders from distributors, as the Company introduced
  Essure
  in several European markets. Cost of sales and start-up
  manufacturing costs were $746,000 in the 2002 first quarter, representing the cost of early stage product introductions and limited production volumes.
  Owing to lower pivotal trial costs, research and development expenses were $2.0 million for the 2002 first quarter, compared with $2.2 million in the prior year's first quarter. Selling, general and administrative expenses were $3.2
  million for the three months ended March 31, 2002, compared with $2.1 million last year. The increase was related to sales and marketing activities as the Company introduced
  Essure
  in the U.K., Northern Ireland, Spain, Portugal, Finland,
  Holland, Belgium and Canada, and continued marketing of
  Essure
  in Australia.
  Cash, cash equivalents, short-term investments and restricted cash
  were $26.5 million as of March 31, 2002, compared with $33.8 million as of December 31, 2001.
  "The past few months have been a time of critically
  important commercial and regulatory progress at Conceptus," said Steven Bacich, chief executive officer. "Much of Conceptus is tightly focused on preparing for an anticipated launch of
  Essure
  in the U.S., making sure manufacturing,
  sales and marketing are in place for a successful market introduction and beyond. Of particular note, last week we reached a tremendous milestone in submitting the
  Essure
  PMA. Clinical data included in our submission will be presented on May
  7, 2002 by Professor Rafael
  2
  Valle, M.D., Northwestern Medical School, at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting, being held in Los
  Angeles.            One key data finding in our PMA submission was the verification of Conceptus' commercial training program, which to date has yielded similar placement success rates
  to those reported by our Pivotal Trial clinical investigators, when compared for the first 10 cases."
  "In addition, we are very pleased with
  the initial introduction of
  Essure
  in Europe, and in close cooperation with our growing distribution network we are working to bring this important method of permanent birth control now to the women of Denmark, Sweden and Germany. There will
  be four clinical presentations and a separate symposium on the
  Essure
  system at the European Society of Gynecological Endoscopy meeting in Berlin, being held April 26-28," continued Mr. Bacich.
  "Our McKesson telephone call center in Australia, designed to provide women with information about permanent birth control options and to answer their questions about
  Essure,
  is fully staffed by healthcare professionals and is off to a strong start. Since its opening in March, we have been able to ease the bottleneck at the General Practitioner level as women may now be initially directed to OB/GYNs
  trained in the
  Essure
  procedure. We plan to incorporate a similar call center format in other countries, including the United States. In addition, we have continued to market directly to the public hospitals in Australia, which represent
  about 70 percent of that nation's tubal ligation procedures, and now are active in public hospitals in every major region there," Mr. Bacich added.
  Separately, the Company announced that it has filed suit against Ovion, Inc. seeking a Declaratory Judgment of Patent Non-Infringement, Invalidity and Unenforceability against Ovion's Patent 6,096,052. "We had already requested an
  interference in the Patent Office in this matter and we plan to vigorously protect our intellectual property rights. Our
  Essure
  device is our first commercial product for permanent contraception and we have no intention of allowing others to
  claim rights to our technology, which we have all worked so diligently to develop and bring to market," commented Mr. Bacich.
  Conceptus has
  scheduled an investor conference call to discuss this announcement beginning at 4:30 p.m. Eastern Time today. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's Website,
  www.conceptus.com. A replay will be available on the Website for 30 days.
  A.    PERMANENT BIRTH CONTROL
  Surgical tubal ligation has become the most common form of birth control worldwide, despite the fact that it is invasive and costly. About 92 percent of
  the laparoscopic procedures in the U.S. are performed in a hospital or surgi-center under general anesthesia, requiring between three and four hours of hospital recovery time and four to six days, before returning to regular activities and an
  average of 10 days for procedures performed via laparotomy. Development of a non-incisional method of tubal ligation has been an elusive goal for researchers since the 1970's.
  3
  An
  Essure
  procedure does not require cutting or penetrating the abdomen and can be performed in a less costly
  procedure setting without general anesthesia. Accordingly, a woman is expected to average about 35 minutes pre-op to post-op for an
  Essure
  procedure and to return home about 45 minutes after the procedure is completed. 92 percent of
  Essure
  patients who were employed returned to work in one day or less, excluding the day of the procedure. Reliance on
  Essure
  does not involve taking drugs or hormones.
  B.    ABOUT CONCEPTUS
  Conceptus, Inc. is developing
  Essure
  , an
  investigational medical procedure, designed to provide a non-incisional alternative to tubal ligation, the leading form of birth control worldwide.
  Essure
  is currently an investigational device in the United States.
  Data from the United Nations show that worldwide, 19 percent of reproductive couples using birth control rely on surgical tubal ligation. Additionally, a survey performed by the
  United States Centers for Disease Control and Prevention indicates that surgical tubal ligation continues to be the most prevalent form of birth control in the U.S., and that 41 percent of women age 35-39 and 50 percent of women age 40-44 have had a
  surgical tubal sterilization. An estimated 700,000 surgical tubal ligations are performed each year in the United States.
  The
  Essure
  procedure is
  based on a unique and proprietary catheter delivery system for minimally invasive transcervical tubal access.
  Except for the
  historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product
  development programs, and clinical efficacy of and market demand for our product, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be
  based upon factors such as strategic planning decisions by management, re-allocation of internal resources, performance of independent distributors, delays by regulatory authorities, scientific advances by third parties, introduction of competitive
  products, as well as those factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and other filings with the Securities and Exchange Commission.
  (Tables to Follow)
  4
  Conceptus, Inc.
  Condensed Consolidated Statements of Operations
  (In thousands, except per share amounts)
  Three Months Ended March 31,
  2002
  2001
  (unaudited)
  Net sales
  $
  276
  $
  —
  Operating costs and expenses:
  Cost of sales and start-up manufacturing costs
  746
  —
  Research and development
  1,982
  2,189
  Selling, general and administrative
  3,214
  2,054
  Total operating costs and expenses
  5,942
  4,243
  Operating loss
  (5,666
  )
  (4,243
  )
  Other income (expense), net
  (189
  )
  187
  Net loss
  $
  (5,855
  )
  $
  (4,056
  )
  Basic and diluted net loss per share
  $
  (0.36
  )
  $
  (0.35
  )
  Shares used in computing basic and diluted net loss per share
  16,471
  11,723
  5
  Conceptus, Inc.
  Condensed Consolidated Balance Sheets
  (In thousands)
  March 31, 2002
  December 31, 2001
  (unaudited)
  Cash, cash equivalents, short-term investments and restricted cash
  $
  26,496
  $
  33,803
  Accounts receivable, net
  304
  247
  Inventories, net
  1,442
  1,134
  Other current assets
  801
  556
  Total current assets
  29,043
  35,740
  Property and equipment, net
  1,748
  1,658
  Other assets
  356
  380
  Total assets
  $
  31,147
  $
  37,778
  Total liabilities
  $
  3,372
  $
  4,603
  Common stock and additional paid-in capital
  118,856
  118,397
  Other comprehensive loss
  (4
  )
  —
  Accumulated deficit
  (91,077
  )
  (85,222
  )
  Total stockholders' equity
  27,775
  33,175
  Total liabilities and stockholders' equity
  $
  31,147
  $
  37,778
  *
  Derived from audited financial statements.
  # # #
  6
  SIGNATURES
  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  CO
  NCEPTUS, INC.
  (Re
  gistrant)
  By
  :
  /s/    Glen K. Furuta
  Glen K. Furuta
  Vice President, Finance & Administration
  and Chief Financial Officer
  Dated:    April 29, 2002
  7